Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans‐splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization

Joseph Ralph Kallini, Ahmed Gabr, Laura Kulik, Daniel Ganger, Robert Lewandowski, Bartley Thornburg, Riad Salem – 28 December 2015

Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans‐splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization

Joseph Ralph Kallini, Ahmed Gabr, Laura Kulik, Daniel Ganger, Robert Lewandowski, Bartley Thornburg, Riad Salem – 28 December 2015

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal – 24 December 2015 – Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus ≥65 years among subjects enrolled in phase 3 trials.

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek – 24 December 2015 – Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation.

Subscribe to